Drug Profile
Tocilizumab biosimilar - Zhejiang Hisun Pharmaceutical
Alternative Names: HS 628Latest Information Update: 24 Nov 2023
Price :
$50
*
At a glance
- Originator Zhejiang Hisun Pharmaceutical
- Class Anti-inflammatories; Antineoplastics; Antirheumatics; Immunotherapies; Monoclonal antibodies; Skin disorder therapies; Vascular disorder therapies
- Mechanism of Action Interleukin 6 receptor antagonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Phase III Rheumatoid arthritis
- Phase I Juvenile rheumatoid arthritis
Most Recent Events
- 14 Jun 2023 Pharmacokinetics and adverse event data from a phase I trial in Juvenile rheumatoid arthritis (In volunteers)released by Hisun Pharmaceutical
- 28 Dec 2020 Phase-III clinical trials in Rheumatoid arthritis in China (IV) (NCT06048224)
- 23 May 2019 Phase-I clinical trials in Juvenile rheumatoid arthritis (In volunteers) in China (IV) (CTR20190620)